Fulvio Braido , MD,Angelica Tiotiu , MD, PhD,Guillermo Guidos-Fogelbach , MD, PhD(c),Ilaria Baiardini , MD,Filippo Cosini , MD,Jaime Correia de Sousa , MD, PhD,Andras Bikov , MD, PhD,Sylvia Novakova , MD, PhD,Marina Labor , MD,Igor Kaidashev , MD,Denislava Nedeva , MD, PhD,Krzysztof Kowal , MD, PhD,Stefan Mihaicuta , MD, PhD,Marilyn Urrutia Pereira , MD,Dirceu Solé , MD,Plamela Novakova , MD,Herberto Chong-Neto , MD, PhD,Laura Vrzy , MD,Ignacio J. Ansotegui , MD, PhD,Jonathan A. Bernstein , MD,Louis-Philippe Boulet , MD, PhD,Giorgio Walter Canonica , MD,Lawrence Dubuske , MD, PhD,Carlos Nunes , MD, PhD,Juan Carlos Ivancevich , MD, PhD,Pierachille Santus , MD, PhD,Nelson Rosario , MD, PhD,Alexander Emelyanov , MD &Paschalis Steiropoulos , MD, PhD
Objective: The optimal use of drug combinations for the management of asthma is providing significant results. This has prompted Interasma (Global Asthma Association) to take a position on inhaled triple therapy in asthma.
Methods: We performed an extensive literature research to clinical trials, meta-analyses, randomized controlled trials and systematic reviews.
Results: Starting from an extensive literature review, Interasma executive committee discussed and approved this Manifesto, developed by Interasma scientific network (INES) members.
Conclusions: The manifesto describes the evidence gathered to date and states, advocates, and proposes issues on inhaled corticosteroid (ICS) plus long-acting beta 2 agonist (LABA) and long-acting muscarinic antagonists (LAMA) with the aim of challenging assumptions, fostering commitment, and bringing about change.